This site is intended for health professionals only

Published on 8 September 2010

Share this story:
Twitter
LinkedIn

New patient safety guidance leads to a rationalisation of insulin pen devices

teaser

New guidance sees the range of insulins provided by sanofi-aventis made available to patients with diabetes in a choice of two of its most modern and contemporary pen devices, SoloSTAR (pre-filled pen device) and/or ClikSTAR (re-usable pen device). All of the company’s insulins will be available in the ClikSTAR and Lantus, Apidra and Insuman Comb 25 will additionally be available in the SoloSTAR. The older pen devices1 will be discontinued from 31st December 2011.

This simplification of the insulin pen devices portfolio follows the provision of guidance on the reduction of insulin-related errors from the National Patient Safety Agency (NPSA) and will ensure that all insulins from sanofi-aventis will be available to patients in one or both of its two high-tech, user-friendly pens.

As sanofi-aventis has announced the withdrawal fifteen months in advance, this will give doctors and patients plenty of time to manage any change necessary. Even patients who only see their doctors once per year will be able to wait until their next routine check, rather than having to make a special visit just to change their pen device.

Stephen Church, Diabetes Franchise Director, sanofi-aventis says, “Patient safety is paramount to us and we have patients at the heart of everything we do. We have taken the decision to offer patients the best pen device options available in either a reusable or pre-filled format, while maintaining them on their current insulin regimen. We will also work with the relevant patient groups to support people currently using our insulin products as well as those who require advice on all treatment options available to them.”

Sanofi Aventis



Most read




Latest Issue

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine
Share this story:
Twitter
LinkedIn